{
    "2018-11-30": [
        [
            {
                "time": "2023-11-14",
                "original_text": "Novartis' Gilenya Approved in EU for Expanded Population",
                "features": {
                    "keywords": [
                        "Gilenya",
                        "EU",
                        "Expanded Population"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-14",
                "original_text": "Pfizer Stock Edges Into Buy Zone On AbbVie Deal For Humira Biosimilar",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Buy Zone",
                        "AbbVie",
                        "Humira",
                        "Biosimilar"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-14",
                "original_text": "This Biotech Stock Could Launch Its First CRISPR Drug In 2022",
                "features": {
                    "keywords": [
                        "Biotech",
                        "CRISPR",
                        "Drug",
                        "2022"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-11-14",
                "original_text": "Novartis CEO Has One New Breakthrough Drug: It Costs $4 Million",
                "features": {
                    "keywords": [
                        "Novartis",
                        "CEO",
                        "Breakthrough Drug",
                        "$4 Million"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}